Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 1950 | 350.925 |
09:39 ET | 364 | 354.08 |
09:41 ET | 1200 | 354.615 |
09:43 ET | 300 | 354.785 |
09:45 ET | 499 | 352.93 |
09:48 ET | 300 | 352.89 |
09:50 ET | 200 | 354.19 |
09:57 ET | 100 | 354 |
09:59 ET | 158 | 354.54 |
10:01 ET | 300 | 355.17 |
10:03 ET | 600 | 355.9 |
10:06 ET | 200 | 356.42 |
10:08 ET | 500 | 356.21 |
10:10 ET | 1730 | 356.23 |
10:12 ET | 100 | 356.345 |
10:14 ET | 1396 | 357.04 |
10:15 ET | 425 | 356.41 |
10:21 ET | 700 | 355.685 |
10:24 ET | 400 | 355.42 |
10:26 ET | 800 | 354.325 |
10:30 ET | 787 | 354.465 |
10:32 ET | 427 | 353.975 |
10:35 ET | 400 | 353.68 |
10:37 ET | 100 | 355 |
10:39 ET | 100 | 353.685 |
10:42 ET | 500 | 353.62 |
10:44 ET | 814 | 353.26 |
10:53 ET | 125 | 354.065 |
11:00 ET | 100 | 353.915 |
11:02 ET | 4669 | 353.915 |
11:08 ET | 125 | 353.33 |
11:11 ET | 100 | 354.56 |
11:13 ET | 100 | 354.56 |
11:18 ET | 100 | 354.555 |
11:22 ET | 100 | 354.88 |
11:24 ET | 100 | 354.96 |
11:26 ET | 200 | 354.725 |
11:27 ET | 100 | 354.715 |
11:31 ET | 2343 | 354.83 |
11:42 ET | 100 | 355.005 |
11:44 ET | 100 | 355.01 |
11:58 ET | 100 | 355.565 |
12:00 ET | 761 | 355.37 |
12:02 ET | 100 | 355.34 |
12:03 ET | 900 | 355.275 |
12:05 ET | 200 | 355.21 |
12:09 ET | 377 | 355.16 |
12:14 ET | 100 | 355.24 |
12:16 ET | 400 | 355.34 |
12:18 ET | 200 | 355.38 |
12:21 ET | 100 | 355.425 |
12:23 ET | 100 | 355.765 |
12:27 ET | 100 | 355.76 |
12:32 ET | 1063 | 355.395 |
12:43 ET | 100 | 354.825 |
12:48 ET | 312 | 354.19 |
12:50 ET | 100 | 353.83 |
12:52 ET | 400 | 353.685 |
12:54 ET | 200 | 353.565 |
12:56 ET | 100 | 353.05 |
12:59 ET | 141 | 353.9399 |
01:01 ET | 174 | 353.26 |
01:03 ET | 119 | 353.445 |
01:12 ET | 600 | 352.82 |
01:14 ET | 481 | 353.16 |
01:21 ET | 200 | 352.855 |
01:24 ET | 183 | 352.788 |
01:30 ET | 100 | 353.16 |
01:33 ET | 100 | 353.1 |
01:37 ET | 100 | 353.5 |
01:44 ET | 2082 | 352.245 |
01:46 ET | 100 | 352.49 |
01:51 ET | 100 | 352.565 |
01:53 ET | 200 | 352.79 |
02:00 ET | 237 | 352.465 |
02:02 ET | 100 | 352.09 |
02:04 ET | 100 | 352.07 |
02:06 ET | 400 | 352.11 |
02:08 ET | 201 | 351.84 |
02:11 ET | 300 | 351.95 |
02:13 ET | 1100 | 351.68 |
02:18 ET | 302 | 351.79 |
02:24 ET | 100 | 351.41 |
02:31 ET | 1316 | 350.94 |
02:44 ET | 100 | 350.74 |
02:45 ET | 201 | 350.74 |
02:49 ET | 400 | 350.4 |
02:51 ET | 1214 | 350.02 |
02:58 ET | 401 | 350.015 |
03:02 ET | 200 | 350.015 |
03:03 ET | 8000 | 349.19 |
03:05 ET | 400 | 349.185 |
03:07 ET | 200 | 348.625 |
03:09 ET | 100 | 348.77 |
03:14 ET | 100 | 348.84 |
03:16 ET | 100 | 348.755 |
03:18 ET | 800 | 348.83 |
03:20 ET | 900 | 349.255 |
03:21 ET | 400 | 348.94 |
03:25 ET | 1500 | 349.15 |
03:27 ET | 3801 | 349.76 |
03:30 ET | 200 | 349.47 |
03:32 ET | 200 | 349.5 |
03:34 ET | 300 | 349.445 |
03:36 ET | 400 | 349.555 |
03:38 ET | 400 | 349.615 |
03:39 ET | 1100 | 349.49 |
03:41 ET | 1100 | 349.555 |
03:43 ET | 600 | 350.62 |
03:45 ET | 3702 | 350.94 |
03:48 ET | 200 | 350.94 |
03:50 ET | 100 | 351.005 |
03:52 ET | 975 | 350.635 |
03:54 ET | 600 | 350.62 |
03:56 ET | 3131 | 350.54 |
03:57 ET | 1878 | 350.215 |
03:59 ET | 44267 | 350.07 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 15.7B | 16.1x | +8.22% |
Biomarin Pharmaceutical Inc | 13.3B | 51.4x | --- |
Exact Sciences Corp | 12.4B | -69.1x | --- |
Neurocrine Biosciences Inc | 11.5B | 33.8x | +62.04% |
Qiagen NV | 9.9B | 136.8x | +12.66% |
Medpace Holdings Inc | 10.4B | 31.8x | +35.10% |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.7B |
---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $21.75 |
Book Value | $127.23 |
P/E Ratio | 16.1x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | 13.9x |
Operating Margin | 48.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.